The $2.5 million verdict awarded to the plaintiff in the first Risperdal case to go to trial in Philadelphia built momentum for the plaintiffs in the litigation, attorneys said, but it is not a nail in the coffin for Janssen Pharmaceuticals’ defense.
Observers noted that while a significant verdict is helpful for the rest of the plaintiffs in the litigation, there is more to any mass tort than the result of the first case, especially because no two cases are the same.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
